Neutralizing Ability of a Single Domain VNAR Antibody: In Vitro Neutralization of SARS-CoV-2 Variants of Concern
Severe Acute Respiratory Syndrome Coronavirus 2 is the causal pathogen of coronavirus disease 2019 (COVID-19). The emergence of new variants with different mutational patterns has limited the therapeutic options available and complicated the development of effective neutralizing antibodies targeting...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-10-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/23/20/12267 |
| _version_ | 1797472773697699840 |
|---|---|
| author | Blanca J. Valdovino-Navarro Salvador Dueñas G. Isaí Flores-Acosta Jahaziel Gasperin-Bulbarela Johanna Bernaldez-Sarabia Olivia Cabanillas-Bernal Karla E. Cervantes-Luevano Alexei F. Licea-Navarro |
| author_facet | Blanca J. Valdovino-Navarro Salvador Dueñas G. Isaí Flores-Acosta Jahaziel Gasperin-Bulbarela Johanna Bernaldez-Sarabia Olivia Cabanillas-Bernal Karla E. Cervantes-Luevano Alexei F. Licea-Navarro |
| author_sort | Blanca J. Valdovino-Navarro |
| collection | DOAJ |
| description | Severe Acute Respiratory Syndrome Coronavirus 2 is the causal pathogen of coronavirus disease 2019 (COVID-19). The emergence of new variants with different mutational patterns has limited the therapeutic options available and complicated the development of effective neutralizing antibodies targeting the spike (S) protein. Variable New Antigen Receptors (VNARs) constitute a neutralizing antibody technology that has been introduced into the list of possible therapeutic options against SARS-CoV-2. The unique qualities of VNARs, such as high affinities for target molecules, capacity for paratope reformatting, and relatively high stability, make them attractive molecules to counteract the emerging SARS-CoV-2 variants. In this study, we characterized a VNAR antibody (SP240) that was isolated from a synthetic phage library of VNAR domains. In the phage display, a plasma with high antibody titers against SARS-CoV-2 was used to selectively displace the VNAR antibodies bound to the antigen SARS-CoV-2 receptor binding domain (RBD). In silico data suggested that the SP240 binding epitopes are located within the ACE2 binding interface. The neutralizing ability of SP240 was tested against live Delta and Omicron SARS-CoV-2 variants and was found to clear the infection of both variants in the lung cell line A549-ACE2-TMPRSS2. This study highlights the potential of VNARs to act as neutralizing antibodies against emerging SARS-CoV-2 variants. |
| first_indexed | 2024-03-09T20:06:57Z |
| format | Article |
| id | doaj.art-a43a20e8bf6a43acb56eb5baa3b1d2fc |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-09T20:06:57Z |
| publishDate | 2022-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-a43a20e8bf6a43acb56eb5baa3b1d2fc2023-11-24T00:30:17ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672022-10-0123201226710.3390/ijms232012267Neutralizing Ability of a Single Domain VNAR Antibody: In Vitro Neutralization of SARS-CoV-2 Variants of ConcernBlanca J. Valdovino-Navarro0Salvador Dueñas1G. Isaí Flores-Acosta2Jahaziel Gasperin-Bulbarela3Johanna Bernaldez-Sarabia4Olivia Cabanillas-Bernal5Karla E. Cervantes-Luevano6Alexei F. Licea-Navarro7Biomedical Innovation Department, Centro de Investigación Científica y Educación Superior de Ensenada, (CICESE), Ensenada 22860, Baja California, MexicoBiomedical Innovation Department, Centro de Investigación Científica y Educación Superior de Ensenada, (CICESE), Ensenada 22860, Baja California, MexicoBiomedical Innovation Department, Centro de Investigación Científica y Educación Superior de Ensenada, (CICESE), Ensenada 22860, Baja California, MexicoBiomedical Innovation Department, Centro de Investigación Científica y Educación Superior de Ensenada, (CICESE), Ensenada 22860, Baja California, MexicoBiomedical Innovation Department, Centro de Investigación Científica y Educación Superior de Ensenada, (CICESE), Ensenada 22860, Baja California, MexicoBiomedical Innovation Department, Centro de Investigación Científica y Educación Superior de Ensenada, (CICESE), Ensenada 22860, Baja California, MexicoBiomedical Innovation Department, Centro de Investigación Científica y Educación Superior de Ensenada, (CICESE), Ensenada 22860, Baja California, MexicoBiomedical Innovation Department, Centro de Investigación Científica y Educación Superior de Ensenada, (CICESE), Ensenada 22860, Baja California, MexicoSevere Acute Respiratory Syndrome Coronavirus 2 is the causal pathogen of coronavirus disease 2019 (COVID-19). The emergence of new variants with different mutational patterns has limited the therapeutic options available and complicated the development of effective neutralizing antibodies targeting the spike (S) protein. Variable New Antigen Receptors (VNARs) constitute a neutralizing antibody technology that has been introduced into the list of possible therapeutic options against SARS-CoV-2. The unique qualities of VNARs, such as high affinities for target molecules, capacity for paratope reformatting, and relatively high stability, make them attractive molecules to counteract the emerging SARS-CoV-2 variants. In this study, we characterized a VNAR antibody (SP240) that was isolated from a synthetic phage library of VNAR domains. In the phage display, a plasma with high antibody titers against SARS-CoV-2 was used to selectively displace the VNAR antibodies bound to the antigen SARS-CoV-2 receptor binding domain (RBD). In silico data suggested that the SP240 binding epitopes are located within the ACE2 binding interface. The neutralizing ability of SP240 was tested against live Delta and Omicron SARS-CoV-2 variants and was found to clear the infection of both variants in the lung cell line A549-ACE2-TMPRSS2. This study highlights the potential of VNARs to act as neutralizing antibodies against emerging SARS-CoV-2 variants.https://www.mdpi.com/1422-0067/23/20/12267COVID-19 neutralizing antibodySARS-CoV-2single-domain antibodyspike proteinVNAR therapy |
| spellingShingle | Blanca J. Valdovino-Navarro Salvador Dueñas G. Isaí Flores-Acosta Jahaziel Gasperin-Bulbarela Johanna Bernaldez-Sarabia Olivia Cabanillas-Bernal Karla E. Cervantes-Luevano Alexei F. Licea-Navarro Neutralizing Ability of a Single Domain VNAR Antibody: In Vitro Neutralization of SARS-CoV-2 Variants of Concern International Journal of Molecular Sciences COVID-19 neutralizing antibody SARS-CoV-2 single-domain antibody spike protein VNAR therapy |
| title | Neutralizing Ability of a Single Domain VNAR Antibody: In Vitro Neutralization of SARS-CoV-2 Variants of Concern |
| title_full | Neutralizing Ability of a Single Domain VNAR Antibody: In Vitro Neutralization of SARS-CoV-2 Variants of Concern |
| title_fullStr | Neutralizing Ability of a Single Domain VNAR Antibody: In Vitro Neutralization of SARS-CoV-2 Variants of Concern |
| title_full_unstemmed | Neutralizing Ability of a Single Domain VNAR Antibody: In Vitro Neutralization of SARS-CoV-2 Variants of Concern |
| title_short | Neutralizing Ability of a Single Domain VNAR Antibody: In Vitro Neutralization of SARS-CoV-2 Variants of Concern |
| title_sort | neutralizing ability of a single domain vnar antibody in vitro neutralization of sars cov 2 variants of concern |
| topic | COVID-19 neutralizing antibody SARS-CoV-2 single-domain antibody spike protein VNAR therapy |
| url | https://www.mdpi.com/1422-0067/23/20/12267 |
| work_keys_str_mv | AT blancajvaldovinonavarro neutralizingabilityofasingledomainvnarantibodyinvitroneutralizationofsarscov2variantsofconcern AT salvadorduenas neutralizingabilityofasingledomainvnarantibodyinvitroneutralizationofsarscov2variantsofconcern AT gisaifloresacosta neutralizingabilityofasingledomainvnarantibodyinvitroneutralizationofsarscov2variantsofconcern AT jahazielgasperinbulbarela neutralizingabilityofasingledomainvnarantibodyinvitroneutralizationofsarscov2variantsofconcern AT johannabernaldezsarabia neutralizingabilityofasingledomainvnarantibodyinvitroneutralizationofsarscov2variantsofconcern AT oliviacabanillasbernal neutralizingabilityofasingledomainvnarantibodyinvitroneutralizationofsarscov2variantsofconcern AT karlaecervantesluevano neutralizingabilityofasingledomainvnarantibodyinvitroneutralizationofsarscov2variantsofconcern AT alexeifliceanavarro neutralizingabilityofasingledomainvnarantibodyinvitroneutralizationofsarscov2variantsofconcern |